Multiple Knockout of Classical HLA Class II β-Chains by CRISPR/Cas9 Genome Editing Driven by a Single Guide RNA
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Comprehensive knockout of HLA class II (HLA-II) β-chain genes is complicated by their high polymorphism. In this study, we developed CRISPR/Cas9 genome editing to simultaneously target HLA-DRB, -DQB1, and -DPB1 through a single guide RNA recognizing a conserved region in exon 2. Abrogation of HLA-II surface expression was achieved in five different HLA-typed, human EBV-transformed B lymphoblastoid cell lines (BLCLs). Next-generation sequencing–based detection confirmed specific genomic insertion/deletion mutations with 99.5% penetrance in sorted cells for all three loci. No alterations were observed in HLA-I genes, the HLA-II peptide editor HLA-DMB, or its antagonist HLA-DOB, showing high on-target specificity. Transfection of full-length HLA-DPB1 mRNA into knockout BLCLs fully restored HLA-DP surface expression and recognition by alloreactive human CD4 T cells. The possibility to generate single HLA-II–expressing BLCLs by one-shot genome editing opens unprecedented opportunities for mechanistically dissecting the interaction of individual HLA variants with the immune system.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Yoshida, H., Matsui, T., Yamamoto, A., Okada, T., & Mori, K. (2001) · Cell · doi:10.1016/s0092-8674(01)00611-0 · Cited by 4,039
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA
Calfon, M., Zeng, H., Urano, F., Till, J. H., Hubbard, S. R., Harding, H. P., Clark, S. G., & Ron, D. (2002) · Nature · doi:10.1038/415092a · Cited by 2,820
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
CD4 T cells: fates, functions, and faults
Zhu, J., & Paul, W. E. (2008) · Blood · doi:10.1182/blood-2008-05-078154 · Cited by 1,798
The IPD and IMGT/HLA database: allele variant databases
Robinson, J., Halliwell, J. A., Hayhurst, J. D., Flicek, P., Parham, P., & Marsh, S. G. E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1161 · Cited by 1,740
Cited by
PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity
Sugiura, D., Okazaki, I., Maeda, T. K., Maruhashi, T., Shimizu, K., Arakaki, R., Takemoto, T., Ishimaru, N., & Okazaki, T. (2022) · Nature Immunology · doi:10.1038/s41590-021-01125-7 · Cited by 108
Engineering immune-evasive allogeneic cellular immunotherapies
Martin, K. E., Hammer, Q., Perica, K., Sadelain, M., & Malmberg, K. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01022-8 · Cited by 69
Li, Y.-R., Fang, Y., Niu, S., Zhu, Y., Chen, Y., Lyu, Z., Zhu, E., Tian, Y., Huang, J., Rezek, V. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56270-6 · Cited by 69
Lee, J., Sheen, J. H., Lim, O., Lee, Y., Ryu, J., Shin, D., Kim, Y. Y., & Kim, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-74772-9 · Cited by 65
Hoerster, K., Uhrberg, M., Wiek, C., Horn, P. A., Hanenberg, H., & Heinrichs, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.586168 · Cited by 63
Self-citationA CMV-induced adaptive human Vδ1+ γδ T cell clone recognizes HLA-DR
Deseke, M., Rampoldi, F., Sandrock, I., Borst, E. M., Böning, H., Ssebyatika, G. L., Jürgens, C., Plückebaum, N., Beck, M., Hassan, A., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20212525 · Cited by 52
Maguire, C. H., Crivello, P., Fleischhauer, K., Isaacson, D. S., Casillas, A., Kramer, C. S. M., Copley, H. C., Heidt, S., Kosmoliaptsis, V., Meneghini, M., et al. (2024) · HLA · doi:10.1111/tan.15455 · Cited by 34
Self-citationEasmin, F., Sasano, Y., Kimura, S., Hassan, N., Ekino, K., Taguchi, H., & Harashima, S. (2019) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2019.08.004 · Cited by 16
Jürgens, L., Manske, F., Hubert, E., Kischka, T., Flötotto, L., Klaas, O., Shabardina, V., Schliemann, C., Makałowski, W., & Wethmar, K. (2021) · Biomedicines · doi:10.3390/biomedicines9060618 · Cited by 15
Stealth designs to overcome allorejection in engineered cell therapy
Li, Y.-R., Chen, Y., & Yang, L. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.02.008 · Cited by 12
Engineering of human mesenchymal stem cells resistant to multiple natural killer subtypes
Zheng, D., Wang, X., Zhang, Z., Li, E., Yeung, C. K., Borkar, R., Qin, G., Wu, Y., & Xu, R. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.64640 · Cited by 12
HLA-A gene knockout using CRISPR/Cas9 system toward overcoming transplantation concerns
Amiri, F., Ranjbar, M., Pirouzfar, M., Nourigorji, M., & Dianatpour, M. (2021) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-021-00155-y · Cited by 5
Broholm, M., Degett, T. H., Furbo, S., Fiehn, A. K., Bulut, M., Litman, T., Eriksen, J. O., Troelsen, J. T., Gjerdrum, L. M. R., & Gögenür, I. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10226-4 · Cited by 5
HLA molecules: Another challenge for CAR T cell therapy
Salih, I., Fakhkhari, M., Berrougui, H., Khalil, A., Benabdellah, K., Atilla, E., & Sadki, K. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103547 · Cited by 3
Amiri, F., Ranjbar, M., Pirouzfar, M., Nourigorji, M., & Dianatpour, M. (2021) · Figshare · doi:10.6084/m9.figshare.14538971
Blind Spots in HLA Class II Detection Generate Challenges for Antibody and RNA-based Assays
Lockhart, J., Lantz, C. W., & Tambur, A. R. (2025) · Transplantation · doi:10.1097/tp.0000000000005592
Designing universal T cell therapies: strategies to evade natural killer cells
Bushara, O., Linette, G. P., & Carreno, B. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1826738
EASMIN, F. (2019) · Institutional Repositories DataBase (IRDB)
Genetic imprinting of HLA-DP variability on cellular and humoral immunity to cytomegalovirus
Betke, L., Crivello, P., Maaßen, F., Eppler, M.-S., Flossdorf, S., Bolaños, E. A., Bolaños, T. A., Bochtler, W., Eberhard, H., Markert, J., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.118281
Self-citation
Metadata
- Authors
- Crivello, P., Ahci, M., Maaßen, F., Wossidlo, N., Arrieta-Bolaños, E., Heinold, A., Lange, V., Falkenburg, J. H. F., Horn, P. A., Fleischhauer, K., & Heinrichs, S.
- Affiliations
- Essen University Hospital (DE)
- Institute of Experimental Cellular Therapy, University Hospital Essen , 45147 Essen ,
- DKMS Life Science Lab , 01307 Dresden ,
- Leiden University Medical Center (NL)
- Corresponding author
- Crivello, Pietro
- Fleischhauer, Katharina
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-03
- Volume
- 202
- Issue
- 6
- Pages
- 1895-1903
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2912336922
- Semantic Scholar
- 2d392c9a48a47c7555f0e4af20ce6bd4aa9c0557
- Cited by
- 19
- References
- 46
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2022: 2 · 2021: 6 · 2020: 1 · 2019: 2
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- HLA class II, HLA-DRB, HLA-DQB1, HLA-DPB1, CRISPR/Cas9 genome editing, single guide RNA, HLA-DMB, HLA polymorphism, CD4+ T cell recognition
- MeSH terms
- Gene Editing, CRISPR-Associated Protein 9, RNA, Guide, CRISPR-Cas Systems, Humans, Cell Line, Tumor, Gene Knockout Techniques, HLA-DR beta-Chains, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.